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The H2 Blockers' Rx-to OTC Switch:
For Whom Will It Spell Relief?
Tylenol. Advil. Monistat 7. Imodium AD. These are some of the most com-
monly used, widely available, and successful drugs in the United States. All of
them began as drugs only available by a prescription. All of them made a suc-
cessful prescription-only to over-the-counter (Rx-to-OTC) switch through the
switch mechanisms of the Food and Drug Administration (FDA). Due to the
amount of money that pharmaceutical companies can make with an Rx-toOTC
switch, the FDA has received dozens of switch requests in the last few years,
and it expects to receive many more in the near future.
Four of the drugs that either currently have switch applications pending
before the FDA or expect to have switch applications pending before the agency
before the end of the year fall into the category known as histamine2-receptor
antagonists, or H2 blockers. The H2 drugs, which help cure ulcers and other
gastrointestinal disorders, have been available in the United States since 1977,
and are some of the most widely prescribed drugs in the country.
This paper has several aims. First, it will briey explain the FDA mech-
anisms through which a pharmaceutical company can switch its drug to OTC
status. Second, it will describe the reasons that so many companies are eager to
have their drugs make the Rx-to-OTC switch, and highlight some of the other
important interest groups involved in the switch process. Then, it will explain
the particular situation of the H2 blockers: the particular reasons that their
companies want to make the switch, whether and when the switch will happen,
and whether the switch reaily should happen. Because the H2 blockers are so
widely used and widely agreed to be safe, their progression through the FDA
switch process will be instructive for all other companies
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considering making the switch. Finally, the paper will attempt to describe
some possible alternatives and changes to our curent Rx-to-OTC process.
The HZ Blockers
As a preliminary matter, it will be helpful to briey dierentiate among
the HZ blocker drugs currently being discussed as switch candidates, and to
outline the FDA-approved uses of the drugs. Cimetidine, the active ingredient
in SmithKline Beecham's Tagamet, was released as a prescription drug in the
United States in 1977. It is the least potent of the HZ blockers.' Ranitidine, the
ingredient in Glaxo's Zantac, gained FDA approval in 1983, and nizatidine, the
ingredient in Lilly's Axid, entered the U.S. perscnption market in 1988. The
most potent of the HZ blockers is famotidine, which Merck introduced into the
United States as Pepcid in 1987Z
The FDA has approved the prescription of HZ blockers for the treatment of
duodenal and gastric ulcers (including for the prevention of recurrent ulcers),
for gastroesophageal reux disease (GERD), and for acid hypersecretion. De-
spite this limited list of approved uses, doctors also commonly prescribe HZ
blockers o-label for other uses, such as the treatment of non-ulcer dyspepsia
and the prevention of ulcer formation in patients taking regular amounts of
nonsteroidal anti-inammatory drugs (NSAIDs), which may irritate the gas-
trointestinal system.3
1 M. Feldman, Pros and Cons of Over-the-Counter Availability of Histamine2-Receotor
Antagonists. 153 Archives of Internal Medicine 2415, 2416 (1993). 2 Ed. at
2416.
~ Id. at 2415; see also LR. Levine ~Lai, Nizatidine Prevents Peotic Ulceration in High Risk Patients Taking NSAIDs.
153 Archives of Internal Medicine 2449 (1993).
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History of the Prescription to Over-the-Counter Switch4
The idea of making potent medications available to the public without a
physician's approval is not new, nor did it arise with modern consumer advo-
cates and health care cost trimmers. Neither the Biologics Act of 190Z5 nor
the original Food and Drugs Act of 19066 designated that certain drugs or
characteristics in drugs requlred a doctor's prescription. Under federal law, the
manufacturer chose whether to distribute its product through doctors and phar-
macists or directly to consumers. Only narcotic drugs, rst regulated in 1914,
required a physician's prescription.7
In 1938, Congress supplanted the 1906 Food and Drug Act with the Food,
Drug, and Cosmetic Act (FDCA),8 which emphasized armative labeling and
adequate directions for use ,9 but which did not address a prescription-mandatory
class of drugs. Later in 1938, the Food and Drug Administration, without Con-
gressional approval, created with regulations a mandatory prescription status for
drugs.10 Congress nally adopted the FDA's prescription-mandatory classica-
tion in the 1951 Durham-Humphrey Amendments to the FDCA.11 By doing so,
Congress agreed with the FDA that for some drugs, it is impossible to provide
a lay person with adequate directions for use. In x 501(b)( 1) of the post-1951
FDCA, Congress dened a prescription drug as one which either (i) fails into an
explicit, statutory list of habit-forming drugs; (ii) is limited to prescription-only
sale in its New Drug
~ The information in this section largely comes from Peter Barton Hun,
A Le~aI
Framework for Future Decisions on Transferring Drugs from PrescriDtion to
NonDrescription Status 37 Food Drug & Cosmetic U. 427, 428-29 (1982).
~32 Stat. 728 (1902).
6 34 Stat. 768 (1906).
~ 38 Stat. 785 (1914).
8 52 Stat. 1040 (1938), 21 U.S.C. xx 301 et sea. (1976).
~ 52 Stat. at 1051, 21 U.S.C. x352(0. 10 3 Fed. Reg. 3161 (Dec. 38, 1938).
~1 65 Stat. 648 (1951).
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Application (NDA) procedures; or (iii) is not safe for use without a physi-
cian's supervision. The last category, which generally adopted the FDA's reg-
ulation that prescription-only drugs are those that can be adequately labeled
for proper use by a lay person, is the one that presents the heart of the over-
the-counter debate, for it is the only one open to FDA discretion and inter-
pretation. The statute provides guidelines for applying this denition: toxicity,
other potentiality for harmful eect, and methods of use and collateral measures
necessary to use. As we shall see, these guidelines can be expanded to include
almost any concern the FDA has about a drug.
Mechanisms of the Rx-to-OTC switch
Currently, there are three ways in which a drug can make the Rx-to-OTC
switch. The rst is through a petition. The petition process, developed by FDA
regulation in 1956,12 can be instituted by any interested person, not only the
manufacturer of the drug. This petition process is rarely used. The second
method for a switch is through the OTC Drug Review.13 The Drug Review,
initiated by the FDA in 197Z, was established as the OTC component of the
climcal ecacy demonstration required of all drugs under the 1962 amendments
to the FDCA.14 The Drug Review uses a monograph system for categorizing
OTC drugs. The third Rx-to-OTC method is the ling of a supplemental new
drug application (NDA) with the FDA. Under the supplemental NDA process,
the FDA determines whether the drug has been shown to be safe and eective
for OTC use.
1.2 The regulations, and the list of drugs approved through the petition
process, are in 21
C.F.R xx 3 10.200-310.201.
13 21 C.F.R. Pt. 330.
14 76 Stat. 780 (1962).
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The two HZ blocking drugs currently under FDA switch review, cimetidine
and famoditine, are being reviewed under the third method, as supplemental
NDAs. As shall be soon be explained, the supplemental NDA procedure for
switching is attractive to manufacturers because, if successful, the drug manu-
facturer receives a period of market exclusivity for the OTC drug.
Pressures on the FDA to approve Rx-to-OTC switches
The debate surrounding the Food and Drug Administration's decision over
which drugs will be sold over-the-counter and which will require a physician's
prescription involves incredibly high stakes. The OTC market in this country
is worth around $11 billion each year, and it will continue to grow.15 A large
percentage of the increase will likely come from the switch drugs. In 199Z, the
Nonprescription Drug Manufacturers Association estimates that the FDA will
receive more than 50 switch requests from manufacturers before 1997.16 The
pressures on FDA from pharmaceutical manufacturers, generic drug companies,
pharmacists, organized medicine, and consumer groups are intense now and will
only become more intense as the country continues its eorts to lower health
care costs.
Pharmaceutical Manufacturers. Several factors have led the pharmaceutical
industry to its current push for more Rx-to-OTC switches. One of the most
important is the national push to lower health care costs. Managed care in an
already highly competitive industry has reduced the big drug companies' power
to set prices. From 1988 to 199Z the earnings per share of
A. N. Burnstein, Anatomy of a Successful Rx-to-OTC Switch Medical
Marketing &
Media, June 1994, at 10.




the ten largest U.S. drug companies grew by 18 percent each year,17 but
times have changed. Analysts estimate that earnings for the biggest U.S. drug
companies will rise only 4.5 percent in 1995, even though sales will rise 13
percent.18 The switch of a popular drug to OTC status is seen throughout the
industry as, if the pun can be forgiven, the peect prescription for increased
sales and prot margins. Estimates for the power of the switch vary, but all are
encouraging for drug companies: average sales may increase by three- or even
ve-fold.19
Another major reason that pharmaceutical companies are eager to have their
drugs approved for OTC use is that the newly FDA-approved use can extend
their patents on the drugs and provide periods of market exclusivity. In the
next ve years, drugs representing an estimated $13.5 billion each year in sales
will lose their patent protection.20 The end of patent protection means huge
competition from generic drug manufacturers and the driving down of the drug's
price. In 1984, Congress passed the Drug Price Competition and Patent Term
Restoration Act (DPC-PTR)2 1, which strikes a compromise between the name
brand manufacturers and their generic competition. A drug company can get a
three-year period of market exclusivity, in which no generic applications may be
approved, if the company pioneers a new drug through an NDA or supplemental
NDA. The pioneer drug does not have to be a new chemical entity; it can be a
new application of an old chemical entity. This means that by getting the new
OTC use of the old drug formulation
17 5. Tully, Why Drug Prices Will Go Lower Fortune, May 3, 1993, at 56.
18 j. Weber and J. Hamilton, Take Two Aspirin and Call in the Morning
Business Week,
Jan. 9, 1995, at 79.
19 See. e.g. Big Sales. suora note 16; P. Abrahams, OTC Sales Prove Addictive.
Financial
Times, August 21, 1992. at 15.




approved through a supplemental NDA, and conducting new clinical inves-
tigations on the drug, a pharmaceutical company can hold o the approval of
any new applications to create a generic version of their drug for three years.22
The DPC-PTR Act also provides pharmaceutical companies with a patent
extension option, under which the company can receive up to, provided that
certain conditions are met, as many as ve extra years on the term of one of a
drug's patents.23 This part of the law compensates the company for the time
lost on its patent while the drug went through the testing and regulatory phase.
Because of the requirements for a patent extension, it will be more dicult for
companies to take advantage of these provisions for their OTC switch drugs,
but it is certainly possible that a company could receive an extended patent
life with a switch. Both the market exclusivity provisions and the patent term
extension provisions in the DPC-PTR Act clearly gives pharmaceutical rms a
reason to look to get an OTC use of their previously developed drugs approved.
Getting a period of market exclusivity or a patent extended seems even
more attractive to drug companies when they consider their other option for
new income: research, development, and FDA approval of an entirely new drug
compound. Such a process can take over a decade, cost a company hundreds of
millions of dollars, and still not lead to an approved new drug. These daunting
gures have led the industry to the point where it is cutting its research &
development budgets, despite a current dearth of big, new ideas coming through
the research pipeline.24
22 Ellen J. Flannery and Peter Barton Hutt, Balancing Comoetition and Patent Protection in the Drug Industry: The Drug Price Comoetition and
Patent Term Restoration Act ot I2~4J 40 Food Drug & Cosmetic LI. 269, 286-
287 (1985).
23 Id. at 302-307.
24 j~ Weber and J. Hamilton, suora note 18, at 79.
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Consumer Advocates. According to a Heller Research Group Study, 64 per-
cent of Americans would like to have direct OTC access to more prescription
drugs that can be safely self-administered.25 Seeking lower costs, convenience,
and greater selection, consumer groups are pushing for more drugs to be avail-
able on an OTC basis. On the other hand, these same groups, particularly those
representing the elderly, are also concerned with safety and fully informative la-
beling. Organizations and publications are demanding less paternalism from
the government on the distribution of drugs, while they also encourage their
members and readers to be vigilant.26
Organized Pharmacy and Organized Medicine. Physicians and pharmacists
may see their importance and their incomes decline somewhat as more drugs
make the OTC switch. Yet neither group has maintained an adversarial position
to the switch process, as long as each is a part of the decision-making. The FDA
has recognized the importance of having doctors and pharmacists involved in
the switch process: In 1982, the FDA approved the OTC use of metaproterenol,
but when the medical community and an advisory committee objected, the
agency rescinded the switch.27 Organized medicine has much less to lose in
the OTC switches, and can be expected to support the switch of many drugs,
provided that the doctor-patient relationship is not interfered with. Pharmacists
have more to lose from the OTC switches, since OTC drugs can be sold from
almost anywhere, although some studies do show that drug stores are far more
successful in the Rx-to-OTC switch drugs than are non-drug stores such as
grocery stores and convenience shops.28 Organized
25 Study cited in A. Cole, Patient. Treat Thyself. Modern Maturity, Oc-
tober 1993, at ii.
26 Id. at 11; OTC Drugs: Prescriotion for Danger? Consumer Reports, Sept.
1994, 101.
27 48 Fed. Reg. 24925 (June 3, 1983), cited in Peter Barton Hun and
Richard A. Merrill,
Food and Drug Law 2d ed., at 418 (1991).
28 Drug Chains' Advantage in Rx-to-OTC Products Chain Drug Review,
June 20, 1994, 40.
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pharmacy continues to push for a third class, or pharmacy only class of
drugs. This issue will be addressed later in the paper.
The Federal Government and the FDA. The government, as we have ob-
served in the last several years, is intensely concerned with lowering health care
costs in this country. Allowing more drugs to switch to OTC status can help cut
costs in two ways: it may remove the cost of an appointment with a doctor, and
it removes the cost of reimbursement for the drug.29 Of course, because it must
be concerned both with the economy and with the protection of the public, the
federal government's interests in any particular OTC switch are complicated.
Recent FDA activity does show that the government generally sees Rxto-
OTC switches as an important and benecial trend. For example, in 1991 the
FDA created and appointed an expert Nonprescription Drugs Advisory Com-
mittee (NDAC). The NDAC spent a large percentage of 1994 in joint meetings,
discussing possible switches with prescription drug committees, and the Chair
of the NDAC has made speeches encouraging innovation in the OTC arena.30
Further, the FDA is considering future rules on simplifying OTC drug labeling
and making clearer the drug interaction and side eects warnings.31 Such con-
cern by the various divisions in the FDA demonstrates the agency's awareness
that more drugs, and more potent and complicated drugs, will soon be entering
the OTC market.
29 While Medicare does not reimburse patients for the cost of prescription
drugs,
Medicaid and many private health insurance plans do.
30 FDA, The Pink Sheet December 20, 1993, at 16-17.
3~ FDA, The Tan Sheet June 13, 1994, at 1.
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Specic issues of the HZ blockers' Rx-to-OTC applications All of the pres-
sures and interests discussed above apply to the current
battle to get the HZ blocker drugs approved for OTC use. In addition, there
are a few twists in the HZ blockers situation that make their companies even
more concerned with getting the switch.
Exoirin~ Patents. The HZ blockers' manufacturers are exceptionally con-
cerned with patent protection and market exclusivity, as each of them is reaching
the end of its patent life. In fact, SmithKline Beecham's patent on Tagamet's
cimetidine already expired in May of 1994. This helps explain why in December
of 1991 cimetidine became the rst of the HZ blockers to begin the Rx-to-OTC
application process. Despite the fact that the patents on cimetidine have ex-
pired and generic companies can now develop the drug, if the OTC switch is
approved, SmithKline Beecham will be the only company allowed to market
cimetidine on the OTC market for a three year period.
Glaxo, the producers of Zantac, has had its own patent troubles. Zan-
tac/ranitidme is the most commercially successful of all the HZ blockers.3Z
Glaxo holds a form 1 patent on ranitidine which will expire in 1995, and a form
Z patent which will expire in 2002. Comfortable with the extra patent life,
Glaxo allowed itself to fall behind in the OTC development process. The form 2
patent on ranitidine narrowly escaped a challenge by a generic drug company in
1993.~~ In response to these patent pressures and the realization that cimetidine
was already before the FDA and that famotidine would be before the end of the
year, Glaxo has refocused its eorts towards getting an OTC switch application
before the FDA.34 Clearly, all the HZ manufacturers are aiming for a period of
OTC market exclusivity for their drugs.
32 FDA, The Pink Sheet March 9, 1992, at T&G-1.
~ Glaxo. Inc. v. Novooharm. Ltd.. 830 F.Supp. 871(1993).
3~ FDA, The Pink Sheet February 1, 1. 993, at T&G-l,2.
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Less Use of H2 Blockers for Ao~roved Rx Uses. It is common practice among
U.S. physicians today to prescribe drugs for uses that are o-label, in other
words, that have not been approved by the FDA. Because of the slowness and
the expense of getting a new use approved by the FDA, reputable and extensive
research on new uses of drugs often appears long before FDA approval does.
This practice is particularly common with the HZ blockers, where symptom
relief leads patients to request the medicine, and the safety of the HZ blockers
relieves physician's worries about the o-label use. In 1990, it was estimated that
more than 60 percent of the revenue manufacturers derive from the sale of HZ
blockers may emanate from the use of these drugs in nonapproved indications.35
Even since the 1990 estimates, important research on peptic ulcers has al-
most certainly led to an increase in the proportion of HZ blockers that are
prescribed for o-label uses. While the HZ blockers are very eective at healing
peptic ulcers, they do not eectively prevent new ulcers from forming. More
than 50 percent of patients whose ulcers are healed using HZ blockers will suer
a relapse within the year; 25 percent will suer a relapse even if they continue
to take the medicine at the daily, prevention-aimed dosage.36 However, begin-
ning in 1982, researchers began to discover a link between heliobacter pylon, a
bacterium, and peptic ulcers, and in February of 1994, the National Institutes
of Health ocially announced the connection, proclaiming that by treating the
heliobacter infection with antibiotics, the relapse rate of ulcers can be reduced
by 90 percent.37 This new information has led to a standard of care of ulcers
involving antibiotics, and not
35 5. HoIt, Alcohol and H2-Receotor Antagonists; Over the Counter. Under the Table?
85
American Journal of Gastroenterology 516 (1990).
36 Ulcer Freedom Fighters The Economist, March 5, 1994, at 93.
~ Id. at 94.
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necessarily HZ blockers. Currently, since the necessary combination of an-
tibiotics is tough for many patients to take, the proper standard of care is to test
all peptic ulcer patients for the presence of the heliobacrer, and if the bacteria
is found (as it will be between 80 and 90 percent of the time), treat with a com-
bination of an antibiotic, Pepto-Bismol or an HZ blocker, and a proton-pump
inhibitor such as omeprazole.38
This new standard of care for peptic ulcer patients has clear implications
for the manufacturers of HZ blockers. Assuming that heliobacter is discovered,
the doctor may choose not to prescribe an HZ blocker in the treatment. Even
if an HZ blocker remains in the treatment process, it is clear that the overall
need for HZ blockers in ghting ulcers will decrease dramatically. Antibiotic
treatment can prevent most relapses of the peptic ulcers, so there will be little
repeat demand for peptic ulcer treatment. This trend away from use of HZ
blockers in ulcer treatments forces the HZ blocker manufacturers to rely solely
on prescriptions for GERD and o-label uses, and thereby increases the nancial
pressure to go OTC with their products.
Will the switch happen?
The overwhelming consensus among physicians, drug companies. and even
the FDA is that the HZ blockers will eventually be switched to OTC status.39
The only questions seem to be when, and who will get there rst. Currently, the
FDA is considering the NDAs for Tagamet/cimetidine and Pepcid/famoditine,
and Zantac/ranitidine and Axid/nizatidine are likely to le NDAs within the
year. In terms of who will get the OTC approval rst, cimetidine seems to have
the edge. Famotidine is more potent than cimetidine
38 Informal conversation with author's father, who is a gastroenterologist.
39 See Statement by FDA Monograph Review Sta Director William Gilbert-
son, reported in
the FDA Pink Sheet October 4, 1993.
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and can therefore be eective at lower doses, but the supplemental NDA for
cimetidine appeared almost two years before famotidine, so Tagamet HB will
probably be the rst HZ blocker on the OTC market.
The race to be rst out of the OTC gate can carry a big prize for the win-
ner. The HZ blockers will be competing in an already crowded eld of OTC
antacids, so it is likely that the rst manufacturer who is able to advertise di-
rectly to consumers about HZ blockers will dominate the market.40 The period
of market exclusivity discussed above will also increase the spoils of the success-
ful HZ blocker manufacturer. Currently, each of the HZ blocker manufacturers
is spending a great deal of money advertising to doctors in order to create a
brand loyalty with patients, so that when the drugs go OTC, there will already
be substantial name recognition. Such Rx-to-OTC strategies have proven suc-
cessful for American Home Products' Advil and Proctor & Gamble's Alleve.41
To aid them in their race for OTC approval, each of the HZ blocker manufac-
turers has engaged in multi-million dollar joint ventures to develop and market
the OTC versions of their products.42
Important moves toward approval have already been made by the HZ block-
ers' companies. In March of 1993, the FDA's Gastrointestinal Drugs Advisory
Committee concluded that while three of the HZ blockers (cimetidine, raniti-
dine, and nizatidine) caused increased levels of blood alcohol absorption, the
increased levels were of no signicant clinical eect.43 The Committee chose not
to recommend a change in the drugs' prescription labels regarding the alcohol
interaction. This decision by the committee bodes well for the
~ P. Weisz, Rx for Protable Switch to OTC: Brand Before Others loin the Fray
Brandweek, September 12, 1994, at 30.
41 Id at 31.
42 ~ FDA, TheTan Sheet July 4, 1994, at 13-15; FDA, The Pink Sheet
August 2,
1993, at 9; FDA, The Pink Sheer August 24, 1992, at 5.
~3 FDA, The Pink Sheet. March 22, 1993, at 4.
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prospects of an OTC switch: although the FDA could certainly require
armative labeling about interactions with alcohol in the future, the fact that
the committee ruled the interactions insignicant means that one more hurdle
to switch approval has been cleared.
The HZ blockers' manufacturers have suered two sets of major setbacks in
their NDA approval process. The rst involves the ecacy of their products at
the OTC doses. In September of 1993, the FDA's Nonprescription Drugs and
Gastrointestinal Drugs Advisory Committees unanimously agreed that SmithK-
line Beecham's clinical trials were unable to demonstrate that cimetidine relieves
heartburn symptoms at its OTC strength.44 The committees expressed that the
OTC-strength cimetidine showed no signicant advantages over OTC antacids.
However, at the same joint meeting, the drug manufacturers received some good
news as well. The committees unanimously agreed that cimetidine is safe enough
to be marketed as an OTC heartburn remedy, and voted 10-4 that all concerns
about drug-drug interactions could be overcome by eective labeling.45
The same advisory committees changed their tune about the danger of drug-
drug interaction at their joint meeting in July of 1994, and dealt the HZ blockers'
manufacturers another setback. At this meeting, the committees were satised
with Sm.ithKline Beecham's new OTC dosing regimen for cimetidine and with
the new ecacy data on heartburn treatment, but voted 12-1 against recom-
mending approval for the OTC switch because of concerns about drug-drug
interactions.46 Merck, the maker of famotidine, also suered
~ FDA, The Tan Sheer September 13, 1993, at 1.
~ Ed. at 1-2.
46 FDA, The Tan Sheet August 1, 1994, at 4-6.
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a setback at the July 1994 meetings, as the committees were critical of that
company's ecacy test results.47
In response to these setbacks, many have questioned whether the mood at
FDA regarding OTC switches has changed.48 It seems possible that the FDA
may be looking for a higher standard of safety and ecacy in switches than it
requires in prescription drugs,49 and such a policy does not seem unreasonable
considering that patients do not necessarily have the advice and supervision
of their doctors when they choose an OTC drug. However, these setbacks for
the HZ blockers will probably approve to be temporary. Other recent switches,
including Syntex's Naprosyn, suered a similar level of scrutiny and setbacks,
and have still enjoyed successful switches. In fact, the committees voted that
the OTC switch of cimetidine could be approved without further committee
review, provided that the drug interaction studies return satisfactory results.50
Does the switch make sense?
As the above discussion demonstrates, the interests at stake in a Rx-toOTC
switch of the HZ blockers will most likely lead to the drugs' appearance on
the over-the-counter market within the next few years. Nevertheless, there
is an unanswered question buried deeply and almost lost in the economics of
the whole debate: does the switch, from a medical and patient care-oriented
perspective, make sense?
'~7 Setbacks Galore suora note 20.
See. e.g. suora note 20.
~9 FDA, The Tan Sheet October 24, 1994, at 2.
~0 FDA, The Tan Sheet August 1, 1994, at 4.
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In analyzing this question, I will use the guidelines provided by Congress
in the Durham-Humphrey Amendments to the FDCA.51 As discussed above,
the relevant clause of the law here is x 503(b)(1)(B). which says that if a drug
is not safe for use without a physician's supervision, it should be available by
prescription only. The statute provides guidelines for applying this denition:
toxicity, other potentiality for harmful eect, and methods of use or collateral
measures necessary to use,
I~i~ixy In this category, the H2 blockers are excellent switch candidates.
The H2 blockers are less toxic than many drugs currently on the OTC market.
Cimeditine, the drug in Tagamet, has in particular undergone a tremendous
amount of safety testing, but all the H2 blockers have been tested in clinical trials
and in post-marketing trials, and none show a signicant amount of adverse
from treatment with the drugs.SZ The toxicity of the drugs is low, and the
serious non-reversible reaction is extremely rare. In addition, the experience in
Denmark, whose government switched cimetidine and ranitidine to OTC status
in 1989, has shown no increase in adverse reactions to the drugs.53
Other ~otentialitv for harmful eect. This broader category allows the con-
sideration of ways in which a relatively non-toxic drug may harm its users, and
has been used by the FDA to consider the potential for dangerous
51 The reader may be interested to know that, of all the medical literature
analyzing the
pros and cons of an OTC switch for the H2 blockers the author read while
researching this
paper, not one mentioned Durham-Humphrey. I found this phenomenon
interesting, but
for the subject of another paper.
52 See. e.g. M. Andersen and J. Schou, Adverse Reactions to H2-Receotor Antagonists
Before and After Transfer of Cimeditine and Rainitidine to OTC Status 69 Jour-
nal of Pharmacology and Toxicology 253(1991); J.B. Porter ~ Long-term Follow-up
Study of ~Jm~ditine 4 Pharmacotherpy 381 (1984).
53 Andersen and Schou, ~ Andersen and Schou, Safety Implications of the OTC Availability of HZ-Antagonists.
8 Drug Safety 179 (1993). It should be noted, however, that the Danish results
also show that most people using H2 blockers are still choosing to get a pre-
scription for the drug, probably in order to receive reimbursement for it.
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drug-drug interactions and for abuse by the users of the drug.54 As men-
tioned above, there is enough concern about the drug-drug interactions with
HZ blockers that the advisory panels considering the HZ blockers' switch or-
dered further studies. However, it seems that these concerns will be assuaged
by the on-going tests, and by informative labeling. Given that drug interaction
concerns are present regarding many of our OTC drugs today, including most
OTC antacids, and given an increasingly informed marketplace of consumers,
the possible drug interactions with the HZ blockers should not keep the product
from OTC status.
However, the HZ blockers, while relatively non-toxic, do present a potential-
ity of harmful eect for their users. The drugs present enormous possibilities
for misuse that could cause harm. The HZ blockers will be switching to the
OTC market at a much lower dose than is available with a prescription, and
it will be switching to the OTC market only for relief of heartburn and upset
stomach. This situation presents the problem that many purchasers of the drug
may, simply by doubling or tripling the approved OTC dosage of the drugs, take
themselves out of the safe range of the drug. Of course, this argument might
be made about almost any drug sold OTC, but it seems particularly likely that
people will over-medicate themselves with the HZ blockers because they will
be looking for immediate relief of dyspepsia. When the drug doesn't provide
quick relief, and it should be noted that dyspepsia relief actually comes slower
(and lasts longer) with the OTC dose of HZ blockers than it does with OTC
antacids,55 chances are that the consumer will simply take several pills until
he or she feels better. There is a serious potential for harmful eect in this
situation, and the situation seems common
~ Hutt, suora note 4, at 435.
~ S. Holt, OTC Histamine H2-Receotor Antagonists 47 Drugs 1, 8 (1994).
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enough that perhaps the FDA should take better note of it. In addition,
there seems to be potential for harmful eect and abuse of the OTC HZ blockers
in the fact that many people may use the new availability of the HZ blockers
to treat their ulcers or suspected ulcers. This situation seems very dangerous
and very possible, yet it is unclear whether discussions by the expert advisory
committees have addressed it. No one has argued that lay persons can safely
treat their own ulcers, and the new information about antibiotic treatments for
ulcers makes such a suggestion even less likely, yet it seems that such misuse of
the OTC HZ blockers will certainiy occur.
Method of use or collateral measures necessary for use. This consid-
eration, clearly the broadest of the FDCA's provisions, allows the FDA to weigh
general questions such as the ability of patients to successfully treat themselves
using the HZ blockers and social policy.56 One of the factors that the FDA
may consider is whether the condition for which the drug is to be used can be
self-diagnosed by a lay person; however, self-diagnosis of the problem is not a
prerequlsite for an OTC switch of the treatment. Even if self-diagnosis were
required, the HZ blockers might pass this test. Dyspepsia is a term with no
precise denition, yet most lay persons are probably capable of knowing when
they feel it, particularly if a physician has already diagnosed it once for them.57
It is true that dyspepsia and similar pain may be a symptom of a larger problem
that lay persons cannot diagnose, this concern is certainly equally present with
other drugs currently on the OTC market, including aspirin and antacids.
Another, more important consideration under the general method of use and
collateral measures category is the ability to self-treat with the drug.
56 Hutt, suora note 4, at 436-439. Professor Hutt's analysis provided the
foundation for
the issues I considered in this section of my analysIs.
~ M. Feldman, supra note 1, at 2416.
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It is here that questions about ecacy of the drug at its OTC doses present
themselves. The FDA's ip-op on the ecacy of cimetidine described above
demonstrates the fact that eectiveness of the HZ blockers for their labeled non-
prescription use of relieving non-ulcer-related dyspepsia is far from settled. One
major study, developed with decision analysis techniques and computer models,
estimated that approximately 5.7 million people experience dvspepsia during
any given quarter-year. and that 3.5 million, or 61.8 percent, of these people
are currently self-medicating with antacids. The study predicted that with
OTC availability of HZ blockers, the number of people who will self-medicate
during a quarter will increase to 3.8 million, or to 64.1 percent. The model
further predicts that the increased self-medication and the eectiveness of the
H2 blockers will increase the proportion of people who obtain complete relief
from dyspepsia from the current 37.9 percent to 43.? percent.58 Unfortunately,
~ '~'r'iies are less enthusiastic about the Mf~~ctP~eness of th~ loiAr-Iiose H?
blockers.59 While the eectiveness of H? blockers in alleviating acid-related
symptoms is recognized, there is no scientic consensus that they are eective,
particularly at lower doses, at relieving non-ulcer dy~pepsia.6O
Besides ecacy. other issues that arise under the self-treatment question
include the possibility that the OTC availability of the drug will.. rather than
helping people heal themselves faster, actually lead their health to deteriorate.
Given that the HZ blockers are relatively safe, this situation may arise in two
distinct situations. First, most doctors agree that lifestyle factors, such as alco-
hol consumption, smoking, and perhaps stress, play a
G. Oster, et al. The Risks and Benets ot an Rx-to OTC Switch: The Case of
OTC H2
~ 28 Medical Care 834, 844-845 (September 1990).
~ See e.g. 0. Nyren ~ Absence of Theraoeutic Benet from Antacids or Cimeditidine
in Non-Ulcer Dvspepsi~i 314 New England Journal of Medicine 339 (1986).
60 Feldman, sunra note I, at 241 &
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signicant role in the development of dyspepsia61. If patients are able to get
relief of their symptoms from OTC HZ blockers, they may lose the opportunity
for medical advice and intervention. Second, there is a possibility that people
with problems much more serious than dyspepsia, such as malignant ulcers and
gastric cancer, may get relief from OTC HZ blockers that prevents them from
seeking medical care. While it is true that both the lifestyle and the masking
issues also apply to the OTC antacids, the concerns about masking are greater
for the HZ blockers, which are better at masking the symptoms of malignancy
in the upper gastrointestinal tract.62
Many of the factors considered above, such as the drug-drug interactions and
the possibility of HZ blocker therapy masking problems as serious as cancer, lead
to the essential requirement that the drug be labeled with adequate directions for
use by a lay person. The labeling requirements, discussed earlier, are becoming
more important as more complicated drugs enter the OTC market. It seems
that proper labeling of OTC HZ blockers is possible. The label will need to
include the complete list of drugs to avoid interaction with, warnings about the
limits of safe dosage of the drug, explanations of the symptoms of gastric cancer
and ulcers along with indications that the symptoms mean the consumer should
seek medical care, and of course, the list of possible side eects of the drug. This
is a hefty labeling requirement, but it does not seem unreasonable, particularly
if the drugs' manufacturers agree to provide an advertising campaign that also
addresses these concerns.
The nal step in the FDCA analysis is social policy. In the nal decision
over whether the HZ blockers will make the OTC switch, concerns about social
61 Holt (1990), supra note 35.
62 M.J.S. Langman, Antisecretorv Treatment and PredisDosition to Cancer
in Advances in
Drug Thera~v of Gastrointestinal Ulceration Garner & Whittle, eds, at 67 (1989).
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policy will most likely have the deciding vote. Of course, social policy is
partially determined by all the above aspects of the safe without the supervision
of a licensed practitioner analysis, but it will also be determined, as it will be
in any regulatory agency, by politics. There is a powerful array of interest
groups that want the HZ blockers to make the OTC switch, and therefore the
switch will most likely take place. In addition, the government and the FDA see
two valuable social gains arising from this and other Rx-to-OTC switches: self-
reliant health care consumers who take responsibility for their own health, and
cost savings. While the author agrees that both of these goals are worthy and
should be sought after, the assumption that Rx-to-OTC products will help the
country meet these goals is not proven, and needs to be challenged. For example,
it may be true that less people will miss work due to dyspepsia because HZ
blockers are available OTC and that these people will no longer have to pay for
the doctor's visit in order to get the medicine; however, if a certain percentage
of those people later develop gastric cancer, which responds well to treatment
only if it is diagnosed and treated early,63 the cost savings, in terms of days
missed at work, drug therapy, and doctor visits, may be lost. In addition, it is
important to remember that the Rx-to-OTC switch does not immediately lead
to competition and lower-priced drugs. In fact, the law will grant the switching
HZ blockers periods of market exclusivity that, combined with the tremendous
burst of advertising that accompanies an Rxto-OTC switch, may actually create
a period when the drug increases in price.64
As the discussion in this section indicates, following through with the com-
plete FDCA x 503(b)( 1)(B) analysis for the HZ blockers leads to mixed
E~ Holt (1994), suPra noteSS, at 9-10.





results. While the drugs are relatively safe and may lead to cost savings and
more complete relief of dyspepsia than most people have previously achieved,
there are serious concerns about the masking of more serious disease, drug
interactions, and misuse of the OTC versions of the drugs for their prescription
uses. The mixed results of this analysis are probably not unique to the HZ
blockers. Whenever a Rx-to-OTC application comes before the FDA, it will be
faced with these competing interests and goals. Besides making it clear that
the job of the FDA and its advisory committees is not easy, this dilemma raises
the following question...
Is there a better way to do all this?
It seems that some improvements on our drug approval system might make
this process more sensible, less pressured, and maybe less political. I will explore
a few possibilities here.
The third class nossibility. The United States is one of the few developed
countries with only two classes of drugs. Most countries, including all of the
European Community, have a third class of drugs, known as the legend or
pharmacy only class. In these countries, most non-prescription drugs can only
be purchased from licensed pharmacists65. The idea, of course, is that the
pharmacist will serve as the necessary intermediary to supply information and
answer questions about drug interactions, ecacy, possible side eects, and
the like. Because these countries rely on their pharmacists to provide these
important health care provider functions, there is less regulation and testing
and concern about selling drugs without a prescription.
65 In thinking about the third class possibility, I relied largely on two
sources~ our class discussion of the topic, and Gregory M. Fisher's Third Class of Drugs
- A Current View 46 Food Drug & Cosmetic LI 583 (1991).
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The reliance in the pharmacist as the necessary intermediary means that
the governments are free to focus more on cost concerns and social policy when
considering a switch away from prescription-only status. An example of this
phenomenon took place in Denmark, where, in 1989, the government simply
transferred several of the prescription-only drugs, including HZ blockers, to
the OTC list. The government, which runs the health care delivery system in
Denmark, was interested in cutting spending on prescription drug reimburse-
ment and on doctors' consultation fees; it was also seeking to pr'cniir~a~ more
cons1mPri~t liriu1~~ ~ bout self-reliance in health care.66 The government, by
relying on the status of its pharmacists. was able to narrow its focus in making
its decisions.
In the United States, despite the consistent eorts of dierent national phar-
macy organizations working on the state and federal level, the idea of this third
class of dt-uo'~ h~ n~v9r h~n ~iircp~d'ii1 67 Many fnrep'i~ h2vP ~pp~ aligned
behind the FDA's consistent refusal to make any changes that would Doint to
a federal avvroval of the Dharmacv-onlv class: organized medicine. consumer
groups, retail and grocery stores' organizations, organized labor. the Nonorescri-
otion Drug Manufacturers Association, and the Devartment of lustice highlight
the list of those concerned about monopolies. high prices. reduced consumer
choice, and the increased middle-man vower that a pharmacy-only class might
bring. As it has during every major drug policy trend, organized pharmacy is
now making substantial arguments in favor of a i-hire-i class of dri.tgs during
the current Rx-to-C)TC switch atmosphere.68 As the OTC switch of the H2
blockers draws closer, the National Association of Retail
66 K. Kristensen, Denmaric H2 Antagonists OTC. 339 Lancet 418 (1992).
b7 For a thorough review of the third class proponents' arguments over the
years, see
Fisher, suora note 65, at 593-604.





Druggists (NARD) will argue that many of the concerns in favor of keeping
the HZ blockers prescription-only can be solved by allowing the OTC sale of the
drugs only in pharmacies. And once again, there is almost no public support
for NARD's position.
No studies have been done on how much advice is really given at pharmacies
in Europe, but regardless of how well that system really works, it could not
work in the United States. There are many reasons for this, but one of the
primary ones is that the U.S. market is just plain dierent than the European
one. Our system is based much more on competition than is Europe's, and there
are not the same kind of giant supermarkets and chain drug stores in Europe as
there are in the U.S. Even if pharmacists in Europe are truly giving meaningful
advice to their customers, in the modern U.S. pharmacy, where pharmacists are
incredibly busy already, and the clerks who actually complete the transaction
with the customers are relatively uneducated about the drugs, there is no way
that the pharmacists could nd the time to be responsible for advising all the
customers. In addition, the creation of a pharmacy only class of drugs will
probably lead to the imposition of greater tort liability for all pharmacists.
In conclusion, although the idea of a third class of drugs sounds wonderful in
theory, it simply would not work in practice in the United States.
Change the drug manufacturers' incentives. One reason that the battle for
the OTC switch is so urgent for the pharmaceutical companies is that these
companies are not doing the kind of R&D that they have done in the past. Given
the delays, the incredible costs, and the riskiness of new chemical development,
the companies are afraid to invest in new research, so they need an OTC market
to provide their new income source. This trend away from R&D is not a healthy
one for the country. The 1984 DPC-PTR Act helped to give the
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pharmaceutical industry the incentive to continue R&D, but it was not
enough. The time spent waiting for FDA approvals of new drugs and new ther-
apies simply must be reduced somehow. Drug companies cannot be expected
to help bear the burden of reducing health care costs if they lose tremendous
amounts of money every time they try to develop a new product. If the new
drug application process had less delays, the drug companies would not be so
focused and insistent upon OTC switches, so the switch process could move in
a less heated atmosphere.
Establishment of a nernianent. ongoing review mechanism The con-
siderations involved in the Rx-to-OTC switch process are extremely important,
life-or-death concerns. Yet these concerns are not currently addressed by the
FDA until the eleventh hour, when an enormous amount of testing, develop-
ment, and advertising to create loyalty among patients has already been invested
by the drug companies. By the time the supplemental NDAs reach the FDA, the
issue of the OTC switch has already become a political battle, with enormously
powerful interests pushing the FDA toward an OTC approval. Perhaps the es-
tablishment of a permanent mechanism, involved in a constant review process
with the pharmaceutical companies, would create less of a pressured situation.69
The creation of the Nonprescription Drugs Advisory Committee is a valu-
able step in this direction, and NDAC has the potential to develop into a useful,
ongoing forum for experimentation. The NDAC, along with the other commit-
tees and divisions of the FDA, has already shown interest in getting involved in
the switch process at an earlier date and in the development of smaller, phased
clinical trials for the switch review.70 A permanent
69See Hun, ~ note 4, at 440.
70 FDA, The Tan Sheet December 19, 1994, at 5.
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mechanism for the review of data from other countries and analysis of the
issues will be able to keep a steady, ecient pace notwithstanding the economic
and political pressures pushing the debate.
Conclusions
As one researcher has explained, The perceived need for OTC antisecretory
drugs may be more a function of political, economic or commercial interests
rather than any readily apparent clinical requirement for the introduction of
the widespread availability of the HZ-receptor-antagonists 71 This paper has
attempted to explain some of the interests behind the Rx-to-OTC debate in
the context of a specic group of commonly prescribed drugs, and it has tried
to communicate some of the problems in our current switch environment and
some suggestions for improvement. In a society that will push for more OTC
switches, it seems essential that Congress and the FDA be prepared to improve
the Rx-to-OTC switch system.
The wisdom of the likely increase in the pace of drugs that will be switched
from prescription-only to over-the-counter is not an easy thing to analyze. There
is no way to run clinically controlled experiments on the health and economy of
our nation. The social goals of cost-cutting and more consumer responsibility
that will likely induce the FDA to allow the HZ blockers and other drugs to
make the switch are important ones, but it seems important for the FDA to
remember its primary responsibility is for the safety of the American public,
not for the furthering of goals that the whole society must take on together.
71 Holt (1994), suora note 55, at 1.
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